Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 12, 2025
Discovery & Translation
Pain targets in ion channel pathways: an Innovation Distillery spotlight
Upstream regulators of ion channel expression or function are an emerging frontier for novel pain targets
BioCentury | Jan 22, 2025
Deals
Simcere snaps up rights to Fermion’s analgesic, a potential Lilly competitor
BioCentury’s latest Deals Report also includes Regenxbio/Nippon, Merus/Biohaven and Daiichi Sankyo/Glycotope
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Nov 27, 2024
Product Development
The late-stage pancreatic cancer landscape: innovation level modest
PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting
BioCentury | Nov 20, 2024
Deals
Where the Ratio deal fits into Novartis’ radiopharma matrix
The deal grows Novartis’ ligand modality and chelator toolbox, and its focus on Lutathera target SSTR2
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Sep 17, 2024
Deals
Pair of radiopharma deals sees Sanofi dive into 212Pb as ITM gets another 177Lu program
Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more
BioCentury | Jul 24, 2024
Product Development
Benchmarking lead-212: SSTR2 test kitchen
The clinical data available for lead-212 provides initial proof-of-concept for its efficacy and safety in radioligand therapies for cancer
BioCentury | Jul 23, 2024
Product Development
Lead-212’s leading players
Decisions about manufacturing and distribution could be make-or-break for drug developers producing their own lead-212
BioCentury | Jul 22, 2024
Product Development
Battle of the alphas: lead-212 picks up speed in radiopharma
The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale
Items per page:
1 - 10 of 116